贝前列素钠联合盐酸沙格雷酯治疗Fontaine (Ⅰ-Ⅱb)期动脉硬化闭塞症的疗效分析

摘要

Objective:To explore beraprost sodium combined with sarpogrelate hydrochloride with beraprost sodium or single sarpogrelate hydrochloride in the treatment of Fontaine (Ⅰ-Ⅱb) to evaluate the effect of arteriosclerosis obliterans(ASO)period.Methods:328 cases were Fontaine (Ⅰ-Ⅱb) ASO patients as the research object,randomly divided into experimental group and control group,the experimental group of 164 cases,164 cases in the control group.The experimental group was treated by oral beraprost sodium combined with sarpogrelate hydrochloride treatment,the control group was divided into separate oral sarpogrelate hydrochloride (A group) and single oral beraprost sodium (B group),patients were given regular medication and followed up for 3 months.The clinical data of two groups,the changes of microcirculation blood flow and clinical effect were compared.Results:The experimental group of vascular endothelial cell expression of NO and TM was higher than the control group (P<0.05),MCP-1,VCAM-1 expression in the experimental group,γ-IFN,TNF-β,M-CSF lower than the control group (P<0.05),the lower limbs in the experimental group improved circulation (ABI,PSV) than the control group (P<0.05),no significant difference in A group compared with B the curative effect (P>0.05).Conclusion:Beraprost sodium combined with sarpogrelate hydrochloride in the treatment of patients with ASO Fontaine (Ⅰ-Ⅱb) is more effective than single use of beraprost sodium or sarpogrelate hydrochloride,more safe,can significantly improve the clinical symptoms of patients,is worthy of promotion.%目的:探讨贝前列素钠联合盐酸沙格雷酯与单用贝前列素钠或单用盐酸沙格雷酯在治疗Fontaine (Ⅰ-Ⅱb)期动脉硬化闭塞症(arteriosclerosis obliterans,ASO)的效果评价.方法:选取328例Fontaine (Ⅰ-Ⅱb)期ASO患者为研究对象,根据随机数字表法将患者分为实验组和对照组,其中实验组164例,对照组164例.实验组采用口服贝前列素钠联合盐酸沙格雷酯治疗,对照组分为单独口服盐酸沙格雷酯(A组)和单独口服贝前列素钠(B组),两组患者均规律用药3个月并随访.比较两组患者的临床数据、微循环血流变化及临床疗效.结果:实验组血管内皮细胞表达一氧化氮(NO)、血栓调节蛋白(TM)高于对照组(P<0.05),实验组单核细胞趋化蛋白-1(MCP-1)、血管细胞粘附分子-1(VCAM-1)、γ干扰素(γ-IFN)、肿瘤坏死因子β(TNF-β)、巨噬细胞集落刺激因子(M-CSF)表达低于对照组(P<0.05);实验组下肢循环血流改善踝-肱指数(ABI)、动脉收缩期最大流速(PSV)优于对照组(P<0.05);A组与B组相比较疗效无明显差异(P>0.05).结论:贝前列素钠联合盐酸沙格雷酯在治疗Fontaine (Ⅰ-Ⅱb)期ASO患者比单用贝前列素钠或盐酸沙格雷酯更安全、有效,可以显著改善患者临床症状,值得临床推广.